Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008 Dec; 39(12):3297-302.

View in: PubMed

subject areas

Aged
Brain Ischemia
Carotid Stenosis
Cerebral Hemorrhage
Cholesterol, LDL
Coronary Disease
Female
Heptanoic Acids
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia
Ischemic Attack, Transient
Male
Middle Aged
Pyrroles
Randomized Controlled Trials as Topic
Recurrence
Risk
Treatment Outcome

authors with profiles

Larry Goldstein